Science Explorer Back to mapMap
Discussion
Institution · Rocky Mountain Multiple Sclerosis Clinic

Most cited papers from Rocky Mountain Multiple Sclerosis Clinic

Rocky Mountain Multiple Sclerosis Clinic

What are the most cited papers from Rocky Mountain Multiple Sclerosis Clinic?

The most cited paper from Rocky Mountain Multiple Sclerosis Clinic is "The Incidence of Fibromyalgia and Its Associated Comorbidities" (Peter T. Weir, Gregory A. Harlan, Flo L. Nkoy et al., 2006), with 322 citations. Next come "Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing" (200) and "Treatment of Postoperative Anterior Cruciate Ligament Infections with Graft Removal and Early Reimplantation" (158).

Showing 50 of 60 papers. Every paper with more than 8 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The Incidence of Fibromyalgia and Its Associated Comorbidities Peter T. Weir, Gregory A. Harlan, Flo L. Nkoy et al. · JCR Journal of Clinical Rheumatology Jun 2006 322
2 Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing Lana Zhovtis Ryerson, John F. Foley, Ih Chang et al. · Neurology Open access 12 Sep 2019 200
3 Treatment of Postoperative Anterior Cruciate Ligament Infections with Graft Removal and Early Reimplantation Robert T. Burks, Matthew G. Friederichs, Barbara P. Fink et al. · The American Journal of Sports Medicine Mar 2003 158
4 Extended interval dosing of natalizumab in multiple sclerosis Lana Zhovtis Ryerson et al. · Journal of Neurology Neurosurgery & Psychiatry 25 Feb 2016 156
5 The effects of antidepressants on sexual functioning in depressed patients: a review. James M. Ferguson · PubMed 2001 152
6 Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial John F. Foley et al. · The Lancet Neurology 100 authors 25 Apr 2022 116
7 Personal and workplace psychosocial risk factors for carpal tunnel syndrome: a pooled study cohort Carisa Harris Adamson, Ellen A. Eisen, Ann Marie Dale et al. · Occupational and Environmental Medicine Open access 3 May 2013 110
8 Management of worsening multiple sclerosis with mitoxantrone: A review Edward Fox · Clinical Therapeutics Apr 2006 100
9 Dual‐label immunocytochemistry of the active multiple sclerosis lesion: Major histocompatibility complex and activation antigens Takaharu Hayashi, Chikao Morimoto, JACK S. BURKS et al. · Annals of Neurology Oct 1988 99
10 Longitudinal Trajectories of Metabolic Control Across Adolescence: Associations With Parental Involvement, Adolescents' Psychosocial Maturity, and Health Care Utilization Pamela S. King, Cynthia A. Berg, Jonathan Butner et al. · Journal of Adolescent Health Open access 9 Dec 2011 93
11 Air Pollution and Fatal Lung Disease in Three Utah Counties Victor E. Archer · Archives of Environmental Health An International Journal Dec 1990 88
12 Occupationally Related Hydrogen Sulfide Deaths in the United States From 1984 to 1994 Douglas C. Fuller, Anthony J. Suruda · Journal of Occupational and Environmental Medicine Sep 2000 84
13 ARSENIC LEVELS IN FINGERNAILS AS A BIOLOGICAL INDICATOR OF EXPOSURE TO ARSENIC Behnaz Agahian, Jeffrey S. Lee, J.H. Nelson et al. · American Industrial Hygiene Association Journal Dec 1990 70
14 Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing John F. Foley, Susan E. Goelz, Tamara Hoyt et al. · Multiple Sclerosis and Related Disorders 26 Mar 2019 57
15 Defining Total Corporate Health and Safety Costs Significance and Impact William F. Brady, Jean Bass, Royce Moser et al. · Journal of Occupational and Environmental Medicine Mar 1997 52
16 Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study Judith J. Stephenson, David M. Kern, Sonalee Agarwal et al. · Health and Quality of Life Outcomes Open access 2012 49
17 Orbitofrontal cortical thinning and aggression in mild traumatic brain injury patients Daniel J. Epstein, Margaret D. Legarreta, Elliot Bueler et al. · Brain and Behavior Open access 28 Sep 2016 48
18 Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action John F. Foley, Emily Stoker, Kavitha Damal · Biologics Open access Nov 2013 48
19 Genetic traits related to hypertension and electrolyte metabolism. R R Williams, Sandra J. Hasstedt, S C Hunt et al. · Hypertension Open access 1991 45
20 A retrospective analysis of cardiometabolic health in a large cohort of truck drivers compared to the American working population Matthew S. Thiese, Richard Joseph Hanowski, Gary L. Moffitt et al. · American Journal of Industrial Medicine 8 Nov 2017 43
21 Chronic Diffuse Interstitial Fibrosis of the Lung in Uranium Miners Victor E. Archer, Attilio D. Renzetti, Reuben S. Doggett et al. · Journal of Occupational and Environmental Medicine May 1998 41
22 A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis Björn Evertsson, Tammy Hoyt, Angel Christensen et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical Open access Oct 2020 36
23 Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters Nicholas Schwab, Tilman Schneider‐Hohendorf, Tammy Hoyt et al. · Multiple Sclerosis Journal Review 29 Aug 2017 36
24 The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis John F. Foley, Cynthia Carrillo-Infante, Jonathan J. Smith et al. · Multiple Sclerosis and Related Disorders 21 Nov 2019 34
25 Redefining functionality and treatment efficacy in multiple sclerosis John F. Foley, David W Brandes · Neurology 8 Jun 2009 34
26 ESOPHAGEAL APERISTALSIS AND ACHALASIA PRODUCED IN DOGS BY PROLONGED CHOLINESTERASE INHIBITION* Lauran D. Harris, W. D. Ashworth, Franz J. Ingelfinger · Journal of Clinical Investigation Open access Nov 1960 33
27 Pharmacodynamics of natalizumab extended interval dosing in MS Lana Zhovtis Ryerson, Xiaochun Li, Judith D. Goldberg et al. · Neurology Neuroimmunology & Neuroinflammation Open access 5 Feb 2020 32
28 Impact of the OSHA Trench and Excavation Standard on Fatal Injury in the Construction Industry Anthony J. Suruda, Brad Whitaker, Donald S. Bloswick et al. · Journal of Occupational and Environmental Medicine Oct 2002 32
29 Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions Annika Anderson et al. · Annals of Clinical and Translational Neurology Open access 7 Sep 2023 31
30 Analytical validation of a multi‐protein, serum‐based assay for disease activity assessments in multiple sclerosis Ferhan Qureshi, Wayne Hu, Louisa Loh et al. · PROTEOMICS - CLINICAL APPLICATIONS Open access 26 Feb 2023 31
31 Depersonalization, Vertigo and Ménière's Disease James P. Grigsby, Catherine Lee Johnston · Psychological Reports Apr 1989 30
32 Body weight-based natalizumab treatment in adult patients with multiple sclerosis Masami Tanaka, Masako Kinoshita, John F. Foley et al. · Journal of Neurology 6 Feb 2015 29
33 Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis Tanuja Chitnis, John F. Foley, Carolina Ionete et al. · Clinical Immunology Open access 4 Jul 2023 27
34 Treatment and disease management of multiple sclerosis patients Cortnee Roman, Kara Menning · Journal of the American Association of Nurse Practitioners Oct 2017 27
35 Fatal work-related injuries in the U.S. chemical industry 1984–89 Anthony J. Suruda, David Robert Wallace · International Archives of Occupational and Environmental Health Sep 1996 27
36 In Vitro Interaction of Coronaviruses with Primate and Human Brain Microvascular Endothelial Cells Gary F. Cabirac, Ronald S. Murray, Laura McLaughlin et al. · Advances in experimental medicine and biology Book chapterOpen access 1995 26
37 Association of Lung Cancer Mortality with Precambrian Granite Victor E. Archer · Archives of Environmental Health An International Journal Apr 1987 25
38 Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis John F. Foley, Kavita V Nair, Timothy R. Vollmer et al. · Patient Preference and Adherence Open access Jun 2017 24
39 Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis Lana Zhovtis Ryerson, John F. Foley, Gilles Louis Defer et al. · Multiple Sclerosis and Related Disorders Open access 10 Feb 2023 22
40 Lung cancer mortality among residents living near the El Paso smelter. William N. Rom, Gloria Varley, JosephL. Lyon et al. · Occupational and Environmental Medicine Open access Aug 1982 22
41 Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy Patricia Katherine Coyle, John F. Foley, Edward Fox et al. · Multiple Sclerosis Journal Nov 2009 22
42 Effect of an Ozone-Generating Air-Purifying Device on Reducing Concentrations of Formaldehyde in Air Eric J. Esswein, Mark F. Boeniger · Applied Occupational and Environmental Hygiene Feb 1994 19
43 Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis Wen Zhu, Chenyi Chen, Lili Zhang et al. · Brain Communications Open access 31 Oct 2023 17
44 Cooking methods, carcinogens, and diet‐cancer studies Victor E. Archer · Nutrition and Cancer 1988 17
45 Characterization of Zeolite Fiber Sizes Using Scanning Electron Microscopy William E. Wright, William N. Rom, Fahrad Moatamed · Archives of Environmental Health An International Journal Mar 1983 15
46 Important Differences in Accelerometer Cut Points for Quantifying Physical Activity in a Nested Occupational Cohort Matthew S. Thiese · Journal of Exercise Sports & Orthopedics Open access 2013 14
47 Blaming the victim: When disease-prevention programs misfire Joy L. Berrenberg, Daniel Rosnik, Nicki J. Kravcisin · Current Psychology Dec 1990 14
48 Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2) Heinz Wiendl, John F. Foley, Gilles Louis Defer et al. · Neurology and Therapy Open access 24 Jul 2024 11
49 Cytomegalovirus Antibodies in Endolymphatic Sac Biopsies of Patients with Endolymphatic Hydrops and Ménière's Disease I. Kaufman Arenberg, GARY CABRIAC, Stefan Marks et al. · Annals of the New York Academy of Sciences Dec 1997 11
50 Surgery for Solitary Thyroid Nodules: Assessment of Methods to Select Patients at Low Risk for Unsuspected Malignancy in the Unaffected Lobe and the Possible Utility of Preoperative Thyroid Ultrasound 3 Raymond Richard Price, KEITH HORVATH, Francis D. Moore · Thyroid 1993 11

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.